GNI Group
Over 20 years of leadership experience in the pharmaceutical industry. She has held business and strategic leadership positions at multiple multinational pharmaceutical companies in Japan and the United States. Prior to her current position, she served as President of the Japanese subsidiary of GlaxoSmithKline plc. In May 2018, she assumed the position of Representative Director and President of UCB Japan Co., Ltd., the Japanese subsidiary of UCB S.A. in Belgium. Board of Director of EFPIA (European Federation of Pharmaceutical Industries and Associations) Japan Advisor for Economic Diplomacy to the Minister of Foreign Affairs and Foreign Trade of the Kingdom of Belgium Bachelor of Faculty of Pharmaceutical Sciences, Hokkaido University / Pharmacist.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
GNI Group
GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).